Standard

Excipient-free isoniazid aerosol administration in mice: Evaporation-nucleation particle generation, pulmonary delivery and body distribution. / Valiulin, S. V.; Onischuk, A. A.; Baklanov, A. M. et al.

In: International Journal of Pharmaceutics, Vol. 563, 30.05.2019, p. 101-109.

Research output: Contribution to journal › Article › peer-review

Harvard

Valiulin, SV, Onischuk, AA, Baklanov, AM, Dubtsov, SN, An'kov, SV, Tolstikova, TG, Plokhotnichenko, ME, Dultseva, GG & Mazunina, PS 2019, 'Excipient-free isoniazid aerosol administration in mice: Evaporation-nucleation particle generation, pulmonary delivery and body distribution', International Journal of Pharmaceutics, vol. 563, pp. 101-109. https://doi.org/10.1016/j.ijpharm.2019.03.050

APA

Valiulin, S. V., Onischuk, A. A., Baklanov, A. M., Dubtsov, S. N., An'kov, S. V., Tolstikova, T. G., Plokhotnichenko, M. E., Dultseva, G. G., & Mazunina, P. S. (2019). Excipient-free isoniazid aerosol administration in mice: Evaporation-nucleation particle generation, pulmonary delivery and body distribution. International Journal of Pharmaceutics, 563, 101-109. https://doi.org/10.1016/j.ijpharm.2019.03.050

Vancouver

Valiulin SV, Onischuk AA, Baklanov AM, Dubtsov SN, An'kov SV, Tolstikova TG et al. Excipient-free isoniazid aerosol administration in mice: Evaporation-nucleation particle generation, pulmonary delivery and body distribution. International Journal of Pharmaceutics. 2019 May 30;563:101-109. doi: 10.1016/j.ijpharm.2019.03.050

Author

Valiulin, S. V. ; Onischuk, A. A. ; Baklanov, A. M. et al. / Excipient-free isoniazid aerosol administration in mice: Evaporation-nucleation particle generation, pulmonary delivery and body distribution. In: International Journal of Pharmaceutics. 2019 ; Vol. 563. pp. 101-109.

BibTeX

@article{0d9f9319fbf2468780e2cacc7939e1e9,
title = "Excipient-free isoniazid aerosol administration in mice: Evaporation-nucleation particle generation, pulmonary delivery and body distribution",
abstract = " Excipient-free isoniazid aerosol formation and pulmonary delivery in mice are studied. An evaporation-nucleation route is used for the generation of isoniazid aerosol. Particle diameters and number concentrations are measured with an aerosol spectrometer consisting of a diffusion battery, condensation chamber, and photoelectric counter. The pulmonary delivery of isoniazid particles is studied in both nose-only (NO) and whole-body (WB) inhalation chambers for the particle mean diameter and number concentration to be 600 nm and 6 × 10 6 cm −3 , respectively. It is found that the rate of drug systemic absorption in the WB chamber is 27% higher than that for the NO one because of an additional consumption of drug orally from the fur in the WB chamber. The particle deposition efficiency ε in the mouse respiratory tract is measured as a function of mean diameter. The quantity ε is equal to 0.7 for the particle diameter d = 10 nm and decreases to 0.2 with the diameter increasing to 300 nm, and then, at d > 300 nm the deposition efficiency increases with diameter to 0.5 at d = 2000 nm. The bioavailability of the aerosol form of isoniazid (72 ± 10%) is very close to that for the per-oral form (61 ± 10%). ",
keywords = "Aerosol, Isoniazid, Mice, Pharmacokinetics, Pulmonary administration, Lung/metabolism, Isoniazid/administration & dosage, Administration, Inhalation, Biological Availability, Male, Particle Size, Tissue Distribution, Animals, Liver/metabolism, Aerosols, Antitubercular Agents/administration & dosage, VIVO ANIMAL-MODELS, DRUG-DELIVERY, DEPOSITION, TUBERCULOSIS, DIFFUSION BATTERY, THERAPY, SIZE DISTRIBUTION, INHALATION DELIVERY, INFECTION MODEL, PHARMACOKINETICS",
author = "Valiulin, {S. V.} and Onischuk, {A. A.} and Baklanov, {A. M.} and Dubtsov, {S. N.} and An'kov, {S. V.} and Tolstikova, {T. G.} and Plokhotnichenko, {M. E.} and Dultseva, {G. G.} and Mazunina, {P. S.}",
note = "Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",
year = "2019",
month = may,
day = "30",
doi = "10.1016/j.ijpharm.2019.03.050",
language = "English",
volume = "563",
pages = "101--109",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Excipient-free isoniazid aerosol administration in mice: Evaporation-nucleation particle generation, pulmonary delivery and body distribution

AU - Valiulin, S. V.

AU - Onischuk, A. A.

AU - Baklanov, A. M.

AU - Dubtsov, S. N.

AU - An'kov, S. V.

AU - Tolstikova, T. G.

AU - Plokhotnichenko, M. E.

AU - Dultseva, G. G.

AU - Mazunina, P. S.

N1 - Publisher Copyright: © 2019 Elsevier B.V.

PY - 2019/5/30

Y1 - 2019/5/30

N2 - Excipient-free isoniazid aerosol formation and pulmonary delivery in mice are studied. An evaporation-nucleation route is used for the generation of isoniazid aerosol. Particle diameters and number concentrations are measured with an aerosol spectrometer consisting of a diffusion battery, condensation chamber, and photoelectric counter. The pulmonary delivery of isoniazid particles is studied in both nose-only (NO) and whole-body (WB) inhalation chambers for the particle mean diameter and number concentration to be 600 nm and 6 × 10 6 cm −3 , respectively. It is found that the rate of drug systemic absorption in the WB chamber is 27% higher than that for the NO one because of an additional consumption of drug orally from the fur in the WB chamber. The particle deposition efficiency ε in the mouse respiratory tract is measured as a function of mean diameter. The quantity ε is equal to 0.7 for the particle diameter d = 10 nm and decreases to 0.2 with the diameter increasing to 300 nm, and then, at d > 300 nm the deposition efficiency increases with diameter to 0.5 at d = 2000 nm. The bioavailability of the aerosol form of isoniazid (72 ± 10%) is very close to that for the per-oral form (61 ± 10%).

AB - Excipient-free isoniazid aerosol formation and pulmonary delivery in mice are studied. An evaporation-nucleation route is used for the generation of isoniazid aerosol. Particle diameters and number concentrations are measured with an aerosol spectrometer consisting of a diffusion battery, condensation chamber, and photoelectric counter. The pulmonary delivery of isoniazid particles is studied in both nose-only (NO) and whole-body (WB) inhalation chambers for the particle mean diameter and number concentration to be 600 nm and 6 × 10 6 cm −3 , respectively. It is found that the rate of drug systemic absorption in the WB chamber is 27% higher than that for the NO one because of an additional consumption of drug orally from the fur in the WB chamber. The particle deposition efficiency ε in the mouse respiratory tract is measured as a function of mean diameter. The quantity ε is equal to 0.7 for the particle diameter d = 10 nm and decreases to 0.2 with the diameter increasing to 300 nm, and then, at d > 300 nm the deposition efficiency increases with diameter to 0.5 at d = 2000 nm. The bioavailability of the aerosol form of isoniazid (72 ± 10%) is very close to that for the per-oral form (61 ± 10%).

KW - Aerosol

KW - Isoniazid

KW - Mice

KW - Pharmacokinetics

KW - Pulmonary administration

KW - Lung/metabolism

KW - Isoniazid/administration & dosage

KW - Administration, Inhalation

KW - Biological Availability

KW - Male

KW - Particle Size

KW - Tissue Distribution

KW - Animals

KW - Liver/metabolism

KW - Aerosols

KW - Antitubercular Agents/administration & dosage

KW - VIVO ANIMAL-MODELS

KW - DRUG-DELIVERY

KW - DEPOSITION

KW - TUBERCULOSIS

KW - DIFFUSION BATTERY

KW - THERAPY

KW - SIZE DISTRIBUTION

KW - INHALATION DELIVERY

KW - INFECTION MODEL

KW - PHARMACOKINETICS

UR - http://www.scopus.com/inward/record.url?scp=85063754525&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2019.03.050

DO - 10.1016/j.ijpharm.2019.03.050

M3 - Article

C2 - 30928214

AN - SCOPUS:85063754525

VL - 563

SP - 101

EP - 109

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

ER -

ID: 19354349